Alpinvest Partners B.v. Lowers stake in Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD) : Alpinvest Partners B.v. reduced its stake in Amicus Therapeutics by 16.29% during the most recent quarter end. The investment management company now holds a total of 63,203 shares of Amicus Therapeutics which is valued at $438,629 after selling 12,300 shares in Amicus Therapeutics , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Amicus Therapeutics makes up approximately 0.73% of Alpinvest Partners B.v.’s portfolio.

Other Hedge Funds, Including , Blackrock Institutional Trust Company N.a. boosted its stake in FOLD in the latest quarter, The investment management firm added 313,096 additional shares and now holds a total of 3,240,568 shares of Amicus Therapeutics which is valued at $22,489,542. Cqs Cayman Lp added FOLD to its portfolio by purchasing 1,390,000 company shares during the most recent quarter which is valued at $9,646,600. Amicus Therapeutics makes up approx 2.23% of Cqs Cayman Lp’s portfolio. Secor Capital Advisors Lp added FOLD to its portfolio by purchasing 75,692 company shares during the most recent quarter which is valued at $507,893. Amicus Therapeutics makes up approx 0.07% of Secor Capital Advisors Lp’s portfolio.Td Asset Management Inc reduced its stake in FOLD by selling 1,500 shares or 0.86% in the most recent quarter. The Hedge Fund company now holds 172,100 shares of FOLD which is valued at $1,204,700.Emerald Advisers Incpa reduced its stake in FOLD by selling 841,238 shares or 44.33% in the most recent quarter. The Hedge Fund company now holds 1,056,583 shares of FOLD which is valued at $7,100,238. Amicus Therapeutics makes up approx 0.32% of Emerald Advisers Incpa’s portfolio.

Amicus Therapeutics opened for trading at $7 and hit $7.17 on the upside on Friday, eventually ending the session at $7.02, with a gain of 0.14% or 0.01 points. The heightened volatility saw the trading volume jump to 10,30,350 shares. Company has a market cap of $998 M.

On the company’s financial health, Amicus Therapeutics reported $-0.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.36.Analysts expectations of $ .17.

Many Wall Street Analysts have commented on Amicus Therapeutics. BofA/Merrill Initiated Amicus Therapeutics on May 18, 2016 to “Buy”, Price Target of the shares are set at $10.

Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.

Leave a Reply

Amicus Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amicus Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.